Form 4: Vertex Pharmaceuticals EVP Charles Wagner Jr. Reports Acquisition of Common Stock

Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, reports acquiring 6,655 shares of common stock on February 12, 2025, through a restricted stock unit award.

Summary

• Charles F. Wagner Jr., the EVP & Chief Financial Officer of Vertex Pharmaceuticals, filed a Form 4 on February 14, 2025.
• The report details a transaction on February 12, 2025, where Wagner acquired 6,655 shares of Vertex Pharmaceuticals' common stock.
• This acquisition was through a restricted stock unit award.
• The price per share was $0.
• Following the transaction, Wagner directly owns 65,534 shares of Vertex Pharmaceuticals' common stock.
• The restricted stock units vest in installments beginning on February 24, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The acquisition of shares by an executive is generally viewed as a positive sign, but it's not a major event.

Positives

• The acquisition of shares by a high-ranking executive could be interpreted as a positive signal about the executive's confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the restricted stock units suggests a continued commitment to the company for at least the next year.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, which is common in the pharmaceutical industry. It provides transparency into the holdings of key personnel and aligns their interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the executive's stock acquisition as a positive sign of confidence in the company's future.

Key Dates